VIVUS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL ASSESSING ETHANOL-FREE CARMUSTINE AS A COMPONENT OF HIGH-DOSE CHEMOTHERAPY PRIOR TO TRANSPLANT IN PATIENTS WITH HODGKIN OR NON-HODGKIN LYMPHOMA

Reuters · 5d ago

Please log in to view news